TrianglePUBLICATIONS · 22371878
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Blood
- Publication date
- 2012 Apr 12
- First author
- Khoury HJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Khoury HJ
- type
- Author
- name
- Cortes JE
- type
- Author
- name
- Kantarjian HM
- type
- Author
- name
- Gambacorti-Passerini C
- type
- Author
- name
- Baccarani M
- type
- Author
- name
- Kim DW
- type
- Author
- name
- Zaritskey A
- type
- Author
- name
- Countouriotis A
- type
- Author
- name
- Besson N
- type
- Author
- name
- Leip E
- type
- Author
- name
- Kelly V
- type
- Author
- name
- Brümmendorf TH
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Khoury HJ
- type
- Author
- name
- Cortes JE
- type
- Author
- name
- Kantarjian HM
- type
- Author
- name
- Gambacorti-Passerini C
- type
- Author
- name
- Baccarani M
- type
- Author
- name
- Kim DW
- type
- Author
- name
- Zaritskey A
- type
- Author
- name
- Countouriotis A
- type
- Author
- name
- Besson N
- type
- Author
- name
- Leip E
- type
- Author
- name
- Kelly V
- type
- Author
- name
- Brümmendorf TH
- type
- Author
- bibliography ids
- nci-bib-59dd1f0851f22c6f0689f34e
- book metadata
- content sha256
- c284a7e4939ff3db51c602259876d25ac401bb80d0be8af145e5ceab8129c9a1
- document type
- citation
- dois
- 10.1182/blood-2011-11-390120
- electronic publication date
- display
- 2012 Feb 27
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:22371878
- immutable id
- pubmed:22371878@c284a7e4939ff3db51c602259876d25ac401bb80d0be8af145e5ceab8129c9a1
- journal
- abbreviation
- Blood
- issn electronic
- 1528-0020
- issn print
- 0006-4971
- issue
- 15
- name
- Blood
- nlm unique id
- 7603509
- pages
- 3403-12
- volume
- 119
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 22371878
- provenance
- batch id
- b6284687e167e7da9556
- provider
- NCBI PubMed ESummary
- record sha256
- 30133f08411805f2a233e1d3f7a2d7792ce92f04c5286996557a4edbbab6b9ce
- response sha256
- 64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
- retrieved at
- 2026-09-09T23:46:45.216259+00:00
- publication date
- display
- 2012 Apr 12
- precision
- day
- year
- 2012
- publication types
- Clinical Trial, Phase I
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Preserved source evidence · Not medical advice